Gallagher Lab

The Gallagher Lab, led by Dr. Katherine A. Gallagher, works to improve innate immunity and cell function in diabetic wound healing and other vascular disease within the Conrad Jobst Vascular Research Laboratories.

Current Research in the Gallagher Lab

Led by Dr. Katherine A. Gallagher, the Gallagher Laboratory investigates the role of immunity, inflammation and epigenetics in wound healing, commonly in the setting of diabetes. She is a foremost authority in this translational area, working to advance our understanding of the basic mechanisms, pathways and proteins involved in regulating inflammation in wounds. The goal of this work, motivated in part by Dr. Gallagher's active vascular surgery clinical practice, is to identify new drug targets and therapies to improve wound healing in patients with diabetes and peripheral artery disease (PAD). Recently, her lab has expanded on these common themes and are examining the role of the innate immune system and epigenetics in aortic aneurysm formation and other vascular diseases.


Wounds such as diabetic foot ulcers are a major contributor to the high, and rising, financial impact of diabetes. Wounds that won't heal are the most common reason patients with diabetes are hospitalized, and they are also the top reason for leg, foot or toe amputation in the United States.

About 80,000 amputations due to nonhealing diabetic wounds take place each year in this country, with a high three-year mortality rate -- between 20% and 50%. Although we have made important strides in how we treat diabetes, we have yet to make significant inroads when it comes to secondary implications such as wound healing. While impaired healing has been associated with the state of chronic inflammation that often exists in diabetes, no effective therapeutic approach yet has been identified to repair the disordered inflammation processes in diabetic wounds.

The result is that, to date, we as clinicians have lacked effective options to offer our patients. The goal of the work in our laboratory is to remedy that – to understand how healing processes are impaired in diabetes, identify therapeutic targets and develop effective new approaches so that we can better treat our diabetic patients. Similar to the chronic inflammation seen in diabetic wounds, aortic aneurysm are a leading cause of cardiovascular death and one mechanism for aneurysm development in chronic inflammation secondary to impaired innate immune cells. We are presently investigating how epigenetic alteration in macrophages impact inflammation in AAAs.

Our Approach

Our laboratory investigates the role chronic inflammation and immune cell function play in non-healing wounds and aortic aneurysms as well as other vascular diseases. Our work has revealed systemic changes in the bone marrow. Stem cells from the bone marrow give rise to the immune cells linked to chronic inflammation.

Our lab is focused on identifying how changes at the molecular level impact innate immune cell function in diseases such as diabetic wounds and AAAs. This will enable us to develop new and targeted immune therapies to restore normal  wound healing and decrease AAA development.

Contributions to Science

Research conducted in the Gallagher Laboratory has led to several key contributions to the understanding of impaired wound healing in diabetes and the role of stem cells that are epigenetically programmed towards increased inflammation in diabetes.

Our group looked at the characteristics of macrophages involved in both inflammation and healing and showed how they differ in diabetic wounds. We also were the first to show that epigenetic changes — changes in how genes are expressed that are not caused by a change in the DNA sequence — in bone marrow stem cells lead certain wound macrophages to assume inflammatory rather than reparative states. These changes result in chronic inflammation that impedes healing. We further identified several enzymes and pathways involved, pointing us to new targets for more effective therapeutic approaches.